Spero will receive exclusive worldwide rights (excluding Greater China) to develop, research, manufacture, and commercialize IBI355 (SP001). Innovent will make an upfront payment and be eligible for additional development and regulatory milestone payments under the agreement. With no disclosed amounts in the provided text, the news appears informational rather than price-moving.
Spero will receive exclusive worldwide rights (excluding Greater China) to develop, research, manufacture, and commercialize IBI355 (SP001). Innovent will make an upfront payment and be eligible for additional development and regulatory milestone payments under the agreement. With no disclosed amounts in the provided text, the news appears informational rather than price-moving.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
neutral
Sentiment Score
0.05
